Dose-response of daridorexant in insomnia disorder: An analysis of Phase 2 and 3 studies.

Luyet, Pierre-Philippe; McCall, William V; Bassetti, Claudio L. A.; Braunstein, Guy; Laurent, Johann; Olivieri, Antonio; Hedner, Jan (2024). Dose-response of daridorexant in insomnia disorder: An analysis of Phase 2 and 3 studies. (In Press). Sleep medicine, 121, pp. 315-325. Elsevier 10.1016/j.sleep.2024.07.019

Preview

Text 1-s2.0-S138994572400337X-main.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (4MB) | Preview

OBJECTIVE

Daridorexant is approved for the treatment of insomnia at two dose levels (25 and 50 mg). Dose-efficacy and -safety response relationships were evaluated using Phase 2 and 3 data.

METHODS

Data (N = 2153) from one Phase 2 (daridorexant 5, 10, 25, 50 mg, placebo once daily for 1 month) and two Phase 3 studies (daridorexant 10 and 25 or 25 and 50 mg, placebo once daily for 3 months) were pooled. Dose-response analyses at 1 month of double-blind treatment were performed using a linear regression and a two-stage meta-analysis approach. Efficacy endpoints were polysomnography-derived wake after sleep onset, latency to persistent sleep (LPS), self-reported total sleep time and the Insomnia Daytime Symptoms and Impacts Questionnaire total score (only Phase 3 data for the latter). Safety endpoints were the incidence of total adverse events (AEs) and AEs corresponding to somnolence/fatigue.

RESULTS

Dose-responses for all efficacy endpoints were significant in the observed dose range (both statistical approaches, p < 0.01). All dose-response relationships were linear except for LPS (two-stage meta-analysis) which showed a change in slope above 10 mg without reaching a plateau. No significant dose-response was observed for any AE (both approaches, p > 0.05). The incidence of AEs corresponding to somnolence/fatigue was low at all doses and, without linear assumption (two-stage meta-analysis) there was no dose-dependency (p = 0.369).

CONCLUSIONS

The data support the use of 50 mg as the preferred daridorexant dose in patients with insomnia disorder to provide the greatest opportunity for efficacy with no increased risk for AEs, including somnolence/fatigue, compared to lower doses.

Interest & Impact

Downloads

0 since deposited on 29 Jul 2024
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item